ICU

SeaStar Medical Holding Corporation (ICU) | Rumor.io

SeaStar Medical Holding

ICU

Attention (50-day avg)0%

Attention rank (50-day avg)#1,072

Bullish sentiment (50-day avg)90%

Price to earnings ratio-0.58

Market capitalization15M

Earnings per share-1.89

Dividend yield (TTM)—

Revenue (annual)1.2M

Net income (annual)-12.2M

Social

What share of all stock conversation is about ICU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% 0	0% +0	0% +0

Sep 29

The company SeaStar Medical Holding Corporation ($ICU) is expecting 21 hospital clinics to be recruiting by mid-November 2027, with a goal of treating 339 patients by January 2027.
The company SeaStar Medical Holding Corporation ($ICU) is anticipating a modular review submission to the FDA by tax day 2027, with a potential listing on the USA's #251 list.
The company SeaStar Medical Holding Corporation ($ICU) is projecting a market capitalization of $1.2 billion, with a potential PPS of $545.00 and a 52-week high within reach.

Generated by AI

Sentiment

Of the messages about ICU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	86.67% -13.33	89.58% +0.55	88.95% -0.7	92.45% +4.09
Bearish	13.33% +13.33	10.42% -0.55	11.05% +0.7	7.55% -4.09

Bullish· Aug 13

The company has successfully enrolled 223 patients in the adult AKI trial, with a goal of 339, and has already received FDA approval for pediatric use, which reduces the risk of future approvals.
The company's revenue is growing, with a 82% YoY increase in Q2, and the blended rate is expected to reach 14-16/month by December 2026, with a perfect winter season for flu and other complications.
The company's cash down to $7M from $12M is the real overhang, but the author believes that the company will use the Lincoln SEPA gradually to stabilize the price and recover slowly, potentially reaching $75+ per share.

Bearish· Aug 12

The company's enrollment for the NEUTRALIZE-AKI trial is slower than expected, potentially delaying adult data until late 2027.
The company's sales numbers are "lost for words" and management has repeatedly failed to meet targets, diluting shareholder wealth while still receiving bonuses.
The company is burning over a million dollars per month with less than $6 million in the bank, suggesting a potential liquidity issue.

Generated by AI

Topics

Of the messages about ICU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	95.92%	55.13%
Technical Analysis	0%	0%	4.08%	13.47%
Analysts	0%	0%	0%	17.18%
Controversies	0%	0%	0%	4.08%
Earnings	0%	0%	0%	2.47%
Macro	0%	0%	0%	7.66%

Announcements· Oct 30

The FDA has issued an Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric Patients.
The device is intended for use in children weighing 10 kilograms or more, and the Approvable Letter is a significant step towards its approval.
SeaStar Medical's stock, $ICU, has reacted positively to the news, with a 6.8% increase in pre-market trading.

Technical Analysis· Oct 27

The author notes a potential reversal in ICU's 5-minute downtrend.
The weekly chart for ICU presents a case for a large price move ahead, citing recent short interest, a bullish S1 pull, and upcoming catalysts.
The stock has a gap below its current price, with a target of around $0.94, and a significant short interest of 23% with a 6 million float.

Generated by AI

Community

Of the messages about ICU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.04%	89.94%	79.86%	66.58%
Newcomers	12.96%	10.06%	20.14%	33.42%

Regulars· Sep 29

$ICU's Neutralize-AKI medicine is expected to be available in France by next October/December 2027, and the company is pursuing other medical indications for clinical trials.
The company's 22 million outstanding shares may be a fair assumption in 2 years, with the potential for significant raises to fund future growth.
$ICU's 52-week high is getting closer, with some participants hoping for a continued upward trend and expecting news that could drive the stock higher.

Newcomers· Mar 5

New users are looking into the company's medical technology and its potential for growth in the industry.
There is interest in SeaStar Medical Holding Corporation's recent developments and how they may impact the company's stock performance.
Users are discussing the current market price and the overall sentiment around ICU, speculating about its future prospects.

Generated by AI

News

SeaStar Medical CMO to present at pediatric therapy conference

21h agoInvesting.com

SeaStar Medical at H.C. Wainwright: adult trial looms over small cap

17d agoInvesting.com

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City. The SeaStar Medical presentatio

20d agoYahoo Finance

ICU: Continued Revenue Growth for QUELIMMUNE®

By David Bautz, PhD NASDAQ: ICU READ THE FULL ICU RESEARCH REPORT Business Update YoY Revenue Growth of 82% for QUELIMMUNE SeaStar Medical Holding Corp. (NASDAQ: ICU) is increasingly validating its commercial strategy for QUELIMMUNE, as exhibited by an 82% YoY growth in revenue for the second quarter of 2026, while simultaneously establishing the reimbursement infrastructure and

1mo agoYahoo Finance

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

SeaStar Medical Holding earnings missed by $0.04, revenue fell short of estimates

1mo agoInvesting.com

Also Discussed

Investors talking about ICU also mention

#	Name	Attention
1	Nuwellis, Inc.NUWE	0%+0
2	Ocean Biomedical Inc.OCEA	0%0
3	Cardio Diagnostics Holdings, Inc.CDIO	0%0
4	Femasys Inc.FEMY	0%+0
5	CYTO - Altamira Therapeutics Ltd.	——
6	TransCode Therapeutics, Inc.RNAZ	0%+0
7	TCBP - TC Biopharm (Holdings) Plc	——
8	Tempest Therapeutics Inc.TPST	0%+0
9	Beamr Imaging Ltd. Ordinary ShareBMR	0%0
10	BETS - Bit Brother Limited	——

SeaStar Medical Holding Corporation

Healthcare
Biotechnology

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation. The company’s current product portfolio includes QUELIMMUNE, an FDA-approved treatment for pediatric acute kidney injury associated with sepsis or septic condition requiring renal replacement therapy, along with additional SCD-based programs in adult kidney injury and other serious inflammatory indications. Based in Denver, Colorado, SeaStar Medical operates in the medical technology and specialty devices market, addressing unmet needs in hospital intensive care and renal replacement settings.

Website

Location

3513 Brighton Boulevard

Denver, CO, 80216

United States

Social

What share of all stock conversation is about ICU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% 0	0% +0	0% +0

Sep 29

The company SeaStar Medical Holding Corporation ($ICU) is expecting 21 hospital clinics to be recruiting by mid-November 2027, with a goal of treating 339 patients by January 2027.
The company SeaStar Medical Holding Corporation ($ICU) is anticipating a modular review submission to the FDA by tax day 2027, with a potential listing on the USA's #251 list.
The company SeaStar Medical Holding Corporation ($ICU) is projecting a market capitalization of $1.2 billion, with a potential PPS of $545.00 and a 52-week high within reach.

Generated by AI

Sentiment

Of the messages about ICU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	86.67% -13.33	89.58% +0.55	88.95% -0.7	92.45% +4.09
Bearish	13.33% +13.33	10.42% -0.55	11.05% +0.7	7.55% -4.09

Bullish· Aug 13

The company has successfully enrolled 223 patients in the adult AKI trial, with a goal of 339, and has already received FDA approval for pediatric use, which reduces the risk of future approvals.
The company's revenue is growing, with a 82% YoY increase in Q2, and the blended rate is expected to reach 14-16/month by December 2026, with a perfect winter season for flu and other complications.
The company's cash down to $7M from $12M is the real overhang, but the author believes that the company will use the Lincoln SEPA gradually to stabilize the price and recover slowly, potentially reaching $75+ per share.

Bearish· Aug 12

The company's enrollment for the NEUTRALIZE-AKI trial is slower than expected, potentially delaying adult data until late 2027.
The company's sales numbers are "lost for words" and management has repeatedly failed to meet targets, diluting shareholder wealth while still receiving bonuses.
The company is burning over a million dollars per month with less than $6 million in the bank, suggesting a potential liquidity issue.

Generated by AI

Topics

Of the messages about ICU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	95.92%	55.13%
Technical Analysis	0%	0%	4.08%	13.47%
Analysts	0%	0%	0%	17.18%
Controversies	0%	0%	0%	4.08%
Earnings	0%	0%	0%	2.47%
Macro	0%	0%	0%	7.66%

Announcements· Oct 30

The FDA has issued an Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric Patients.
The device is intended for use in children weighing 10 kilograms or more, and the Approvable Letter is a significant step towards its approval.
SeaStar Medical's stock, $ICU, has reacted positively to the news, with a 6.8% increase in pre-market trading.

Technical Analysis· Oct 27

The author notes a potential reversal in ICU's 5-minute downtrend.
The weekly chart for ICU presents a case for a large price move ahead, citing recent short interest, a bullish S1 pull, and upcoming catalysts.
The stock has a gap below its current price, with a target of around $0.94, and a significant short interest of 23% with a 6 million float.

Generated by AI

Community

Of the messages about ICU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.04%	89.94%	79.86%	66.58%
Newcomers	12.96%	10.06%	20.14%	33.42%

Regulars· Sep 29

$ICU's Neutralize-AKI medicine is expected to be available in France by next October/December 2027, and the company is pursuing other medical indications for clinical trials.
The company's 22 million outstanding shares may be a fair assumption in 2 years, with the potential for significant raises to fund future growth.
$ICU's 52-week high is getting closer, with some participants hoping for a continued upward trend and expecting news that could drive the stock higher.

Newcomers· Mar 5

New users are looking into the company's medical technology and its potential for growth in the industry.
There is interest in SeaStar Medical Holding Corporation's recent developments and how they may impact the company's stock performance.
Users are discussing the current market price and the overall sentiment around ICU, speculating about its future prospects.

Generated by AI

SeaStar Medical Holding

Social

Sep 29

Bullish· Aug 13

Bearish· Aug 12

Announcements· Oct 30

Technical Analysis· Oct 27

Regulars· Sep 29

Newcomers· Mar 5

SeaStar Medical CMO to present at pediatric therapy conference

SeaStar Medical at H.C. Wainwright: adult trial looms over small cap

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

ICU: Continued Revenue Growth for QUELIMMUNE®

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

SeaStar Medical Holding earnings missed by $0.04, revenue fell short of estimates

Also Discussed

SeaStar Medical Holding Corporation

Company Information

Location

SeaStar Medical CMO to present at pediatric therapy conference

SeaStar Medical at H.C. Wainwright: adult trial looms over small cap

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

ICU: Continued Revenue Growth for QUELIMMUNE®

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

SeaStar Medical Holding earnings missed by $0.04, revenue fell short of estimates

Also Discussed

Social

Sep 29

Bullish· Aug 13

Bearish· Aug 12

Announcements· Oct 30

Technical Analysis· Oct 27

Regulars· Sep 29

Newcomers· Mar 5